# Royalty Pharma plc

**RPRX**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001802768

**D**

**fourth fifth of 370 graded peers in healthcare**

rank 237 of 370; percentile 64.0; sampling error 2.5 points; lower is stronger

A B C D E


**D, the sloth**



## Scoreboard


| | |
|---|---|
| **Profitability** | C<br>percentile 47.2 |
| **Solvency** | C/D<br>percentile 59.0 |
| **Growth and financing** | C<br>percentile 53.3 |
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $19.6B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: dilution, distress |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Feb 11, 2026<br>250 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026 |
| **Last close** | $60.97<br>2026-10-16; market equity $23.7B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 11, 2026*

We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*


| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 47.2** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | 8.9% | 9.3% | | 50.7 | 74 | 2025-12-31 |
| Accruals ratio | (9.1%) | (6.6%) | | 43.8 | 812 | 2025-12-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 59.0** | | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | | |
| *liabilities and a nearby cover-page share count are required at 2026-06-30* | | | | | | |
| Altman Z double-prime | 2.25 | (0.30) | | 27.9 | 757 | 2025-12-31 |
| Net debt to EBITDA | 5.33x | 1.82x | | 83.8 | 75 | 2025-12-31 |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 2.40x | 2.96x | | 65.2 | 840 | 2025-12-31 |
| **Growth and financing, sleeve percentile 53.3** | | | | | | |
| Revenue growth, three-year compound | 2.1% | 10.1% | | 66.6 | 414 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *four consecutive annual FCF observations are required; found 0* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | 5.3% | 2.1% | | 39.9 | 705 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.5% | | | | |
| *two annual share counts are required; found 0* | | | | | | |

## Among 370 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 232 | Mannkind Corp. (MNKD) | 62.6 | D | |
| 233 | Biogen Inc. (BIIB) | 62.9 | D | |
| 234 | Lenz Therapeutics, Inc. (LENZ) | 63.1 | D | short runway |
| 235 | AbbVie Inc. (ABBV) | 63.4 | D | |
| 236 | Caribou Biosciences, Inc. (CRBU) | 63.7 | D | short runway |
| 237 | Royalty Pharma plc (RPRX) | 64.0 | D | |
| 238 | Integra Lifesciences Holdings Corp. (IART) | 64.2 | D | |
| 239 | Arvinas, Inc. (ARVN) | 64.5 | D | short runway, fortress balance sheet |
| 240 | Cardiff Oncology, Inc. (CRDF) | 64.8 | D | short runway, fortress balance sheet |
| 241 | Organogenesis Holdings Inc. (ORGO) | 65.0 | D | fortress balance sheet |
| 242 | Fulgent Genetics, Inc. (FLGT) | 65.3 | D | short runway |

## What the price implies

*at the 2026-10-16 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 77.4% | 8.0% | 84 |
| Distance from 52-week high | (4.7%) | (33.0%) | 92 |
| EBIT to enterprise value | 4.9% | (1.7%) | 78 |
| Free cash flow yield | not computable | (1.0%) | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Book value to price | 0.41 | 0.28 | 62 |
| Sales to price | 0.10 | 0.31 | 24 |
| Composite equity issuance, five years | not computable | 20.3% | |
| Relative strength against the sector, log excess return | 0.36 | (0.13) | 84 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $812.0M |
| Operating cash flow, four quarters | $3.0B |
| Months of runway | not finite |
| Days since last periodic filing | 75 (10-Q received Aug 5, 2026) |
| Median daily dollar volume, 63 sessions | $160.3M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | operating income | us-gaap:OperatingIncomeLoss | $1.6B | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 2 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $1.3B | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 3 | income tax | us-gaap:IncomeTaxExpenseBenefit | $0 | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 4 | total debt | us-gaap:LongTermDebt | $9.0B | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 5 | book equity | us-gaap:StockholdersEquityIncludingPortionAttributableT... | $9.7B | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 6 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $618.7M | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 7 | total debt | us-gaap:LongTermDebt | $7.6B | 2024-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 8 | book equity | us-gaap:StockholdersEquityIncludingPortionAttributableT... | $10.3B | 2024-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $929.0M | 2024-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 10 | net income | us-gaap:NetIncomeLoss | $770.9M | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 11 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $2.5B | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 12 | assets | us-gaap:Assets | $19.6B | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 13 | assets | us-gaap:Assets | $18.2B | 2024-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 14 | current assets | us-gaap:AssetsCurrent | $1.5B | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 15 | current liabilities | us-gaap:LiabilitiesCurrent | $636.2M | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 16 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $2.4B | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 17 | liabilities | us-gaap:Liabilities | $9.9B | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 18 | depreciation amortization | us-gaap:Depreciation | $3.9M | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 19 | operating income | us-gaap:OperatingIncomeLoss | $1.5B | 2023-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 20 | interest expense | us-gaap:InterestExpense | $187.2M | 2023-12-31 | 2024-02-15 | 10-K | 24-000012 |
| 21 | revenue | us-gaap:Revenues | $2.4B | 2025-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 22 | revenue | us-gaap:Revenues | $2.3B | 2024-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 23 | revenue | us-gaap:Revenues | $2.4B | 2023-12-31 | 2026-02-11 | 10-K | 26-000003 |
| 24 | revenue | us-gaap:Revenues | $2.2B | 2022-12-31 | 2025-02-12 | 10-K | 25-000010 |
| 25 | assets | us-gaap:Assets | $16.4B | 2023-12-31 | 2025-02-12 | 10-K | 25-000010 |
| 26 | assets | us-gaap:Assets | $16.8B | 2022-12-31 | 2024-02-15 | 10-K | 24-000012 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.